Cargando…

Effectiveness and Safety of Magseed Localization for Excision of Breast Lesions: A Prospective, Phase IV Trial

OBJECTIVE: A prospective, phase IV study was conducted to assess the effectiveness of Magseed to localize breast lesions requiring surgical excision. BACKGROUND: Since Food and Drug Administration approval in 2016, Magseed has been increasingly used to localize nonpalpable lesions due to advantages...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Puneet, Scoggins, Marion E., Sahin, Aysegul A., Hwang, Rosa F., Kuerer, Henry M., Caudle, Abigail S., Mittendorf, Elizabeth A., Thompson, Alastair M., Bedrosian, Isabelle, Teshome, Mediget, DeSnyder, Sarah M., Meric-Bernstam, Funda, Hunt, Kelly K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health, Inc. 2020
Materias:	Original Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130552/ https://www.ncbi.nlm.nih.gov/pubmed/34017965 http://dx.doi.org/10.1097/AS9.0000000000000008

Ejemplares similares

Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy
por: Dominici, Laura S, et al.
Publicado: (2012)

Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy
por: Caudle, Abigail S, et al.
Publicado: (2012)

Targeting and limiting surgery for patients with node-positive breast cancer
por: Caudle, Abigail S., et al.
Publicado: (2015)

Outcomes of Sentinel Lymph Node Dissection Alone vs. Axillary Lymph Node Dissection in Early Stage Invasive Lobular Carcinoma: A Retrospective Study of the Surveillance, Epidemiology and End Results (SEER) Database
por: Wang, Jun, et al.
Publicado: (2014)

The applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy
por: Reitsamer, R., et al.
Publicado: (2021)

Patient and clinician satisfaction and clinical outcomes of Magseed compared with wire-guided localisation for impalpable breast lesions
por: Micha, Aikaterini E., et al.
Publicado: (2020)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

A novel labeling modality of intra-abdominal lesions with Magseed magnetic marker and extirpation by Sentimag probe navigation
por: Toman, Daniel, et al.
Publicado: (2023)

Efficacy and Accuracy of Using Magnetic Seed for Preoperative Non-Palpable Breast Lesions Localization: Our Experience with Magseed
por: D’Angelo, Anna, et al.
Publicado: (2022)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

P151. PREVENTION OF BREAST CANCER RELATED LYMPHEDEMA WITH PROPHYLACTIC LYMPH NODE TRANSFER: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY
por: Chang, Edward I., et al.
Publicado: (2022)

Evaluation of the nonradioactive inducible magnetic seed system Magseed for preoperative localization of nonpalpable breast lesions – initial clinical experience
por: Pieszko, Karolina, et al.
Publicado: (2020)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2015)

Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2016)

Safety and feasibility of breast lesion localization using magnetic seeds (Magseed): a multi-centre, open-label cohort study
por: Harvey, James R., et al.
Publicado: (2018)

Evaluation of Axillary Lymph Node Marking with Magseed® before and after Neoadjuvant Systemic Therapy in Breast Cancer Patients: MAGNET Study
por: Martínez, María, et al.
Publicado: (2022)

Clinical experience of the Magseed(®) magnetic marker to localize non-palpable breast lesions: a cohort study of 100 consecutive cases
por: Crèvecoeur, Julie, et al.
Publicado: (2023)

Cancer Surgery Scheduling During and After the COVID-19 First Wave: The MD Anderson Cancer Center Experience
por: Tzeng, Ching-Wei D., et al.
Publicado: (2020)

Evaluation of 2014 margin guidelines on re-excision and recurrence rates after breast conserving surgery: A multi-institution retrospective study
por: Kuritzky, Anne, et al.
Publicado: (2020)

Progress and Persistent Challenges in Improving Care for Low-Income Women with Breast Cancer
por: Cobb, Adrienne N., et al.
Publicado: (2022)

23rd Annual Meeting of the American Society of Breast Surgeons: Back to In-Person Scientific Exploration
por: Fisher, Carla S., et al.
Publicado: (2022)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel
por: Shen, Chan, et al.
Publicado: (2016)

Efficacy of Quality Criteria to Identify Potentially Harmful Information: A Cross-sectional Survey of Complementary and Alternative Medicine Web Sites
por: Walji, Muhammad, et al.
Publicado: (2004)

Effectiveness Without Efficacy: Cautionary Tale from a Landmark Breast Cancer Randomized Controlled Trial
por: Shen, Yu, et al.
Publicado: (2023)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing
por: Leighton, Jake, et al.
Publicado: (2022)

Adapting a Natural Language Processing Tool to Facilitate Clinical Trial Curation for Personalized Cancer Therapy
por: Zeng, Jia, et al.
Publicado: (2014)

Tetrakis(N,N-diethylcarbamato)titanium(IV)
por: Straessler, Nicholas A., et al.
Publicado: (2007)

Antibody-drug conjugates in lung cancer: dawn of a new era?
por: Coleman, Niamh, et al.
Publicado: (2023)

CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features
por: Mao, Yong, et al.
Publicado: (2013)

Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations
por: Malhotra, Ankit, et al.
Publicado: (2015)

Comparisons of Work-Life Balance Issues in the CERN Member States
por: Desnyder-Ivesdal, M
Publicado: (2001)

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
por: Huang, Licai, et al.
Publicado: (2022)

Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014)

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference
por: Ueno, Naoto T., et al.
Publicado: (2018)

Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types
por: Chen, Tenghui, et al.
Publicado: (2016)

Response to Mammalian Target of Rapamycin–Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation
por: Cuglievan, Branko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4flc6lu7ftfik19tidgiftkvjq